LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset.

    Damsker, Jesse M / Cornish, Michaelyn R / Kanneboyina, Priya / Kanneboyina, Ila / Yu, Qing / Lipson, Rachel / Phadke, Aditi / Knoblach, Susan M / Panchapakesan, Karuna / Morales, Melissa / Fiorillo, Alyson A / Partridge, Terence / Nagaraju, Kanneboyina

    Inflammation research : official journal of the European Histamine Research Society ... [et al.

    2019  Volume 68, Issue 11, Page(s) 969–980

    Abstract: Objective and design: The objective of this study was to assess the effect of vamorolone, a first-in-class dissociative steroidal compound, to inhibit inflammation when administered after disease onset in the murine collagen antibody-induced arthritis ... ...

    Abstract Objective and design: The objective of this study was to assess the effect of vamorolone, a first-in-class dissociative steroidal compound, to inhibit inflammation when administered after disease onset in the murine collagen antibody-induced arthritis model of arthritis.
    Animals: 84 DBA1/J mice were used in this study (n = 12 per treatment group).
    Treatment: Vamorolone or prednisolone was administered orally after disease onset for a duration of 7 days.
    Methods: Disease score and bone erosion were assessed using previously described scoring systems. Cytokines were measured in joints via immunoassay, and joint cathepsin B activity (marker of inflammation) was assessed using optical imaging of joints on live mice.
    Results: We found that vamorolone treatment led to a reduction of several disease parameters including disease score, joint inflammation, and the presence of pro-inflammatory mediators to a degree similar of that observed with prednisolone treatment. More importantly, histopathological analysis of affected joints showed that vamorolone treatment significantly reduced the degree of bone erosion while this bone-sparing property was not observed with prednisolone treatment at any of the tested doses.
    Conclusions: While many intervention regimens in other studies are administered prior to disease onset in animal models, the current study involves delivery of the potential therapeutic after disease onset. Based on the findings, vamorolone may offer an efficacious, yet safer alternative to conventional steroidal compounds in the treatment of rheumatoid arthritis and other inflammatory diseases.
    MeSH term(s) Animals ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/immunology ; Arthritis, Experimental/drug therapy ; Arthritis, Experimental/immunology ; Arthritis, Experimental/pathology ; Collagen Type II/immunology ; Cytokines/immunology ; Joints/drug effects ; Joints/immunology ; Joints/pathology ; Lipopolysaccharides ; Male ; Mice, Inbred DBA ; Pregnadienediols/therapeutic use
    Chemical Substances Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Collagen Type II ; Cytokines ; Lipopolysaccharides ; Pregnadienediols ; VBP15 compound
    Language English
    Publishing date 2019-08-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 1221794-3
    ISSN 1420-908X ; 1023-3830
    ISSN (online) 1420-908X
    ISSN 1023-3830
    DOI 10.1007/s00011-019-01279-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

    Conklin, Laurie S / Damsker, Jesse M / Hoffman, Eric P / Jusko, William J / Mavroudis, Panteleimon D / Schwartz, Benjamin D / Mengle-Gaw, Laurel J / Smith, Edward C / Mah, Jean K / Guglieri, Michela / Nevo, Yoram / Kuntz, Nancy / McDonald, Craig M / Tulinius, Mar / Ryan, Monique M / Webster, Richard / Castro, Diana / Finkel, Richard S / Smith, Andrea L /
    Morgenroth, Lauren P / Arrieta, Adrienne / Shimony, Maya / Jaros, Mark / Shale, Phil / McCall, John M / Hathout, Yetrib / Nagaraju, Kanneboyina / van den Anker, John / Ward, Leanne M / Ahmet, Alexandra / Cornish, Michaelyn R / Clemens, Paula R

    Pharmacological research

    2018  Volume 136, Page(s) 140–150

    Abstract: We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) ... ...

    Abstract We report a first-in-patient study of vamorolone, a first-in-class dissociative steroidal anti-inflammatory drug, in Duchenne muscular dystrophy. This 2-week, open-label Phase IIa multiple ascending dose study (0.25, 0.75, 2.0, and 6.0 mg/kg/day) enrolled 48 boys with Duchenne muscular dystrophy (4 to <7 years), with outcomes including clinical safety, pharmacokinetics and pharmacodynamic biomarkers. The study design included pharmacodynamic biomarkers in three contexts of use: 1. Secondary outcomes for pharmacodynamic safety (insulin resistance, adrenal suppression, bone turnover); 2. Exploratory outcomes for drug mechanism of action; 3. Exploratory outcomes for expanded pharmacodynamic safety. Vamorolone was safe and well-tolerated through the highest dose tested (6.0 mg/kg/day) and pharmacokinetics of vamorolone were similar to prednisolone. Using pharmacodynamic biomarkers, the study demonstrated improved safety of vamorolone versus glucocorticoids as shown by reduction of insulin resistance, beneficial changes in bone turnover (loss of increased bone resorption and decreased bone formation only at the highest dose level), and a reduction in adrenal suppression. Exploratory biomarkers of pharmacodynamic efficacy showed an anti-inflammatory mechanism of action and a beneficial effect on plasma membrane stability, as demonstrated by a dose-responsive decrease in serum creatine kinase activity. With an array of pre-selected biomarkers in multiple contexts of use, we demonstrate the development of the first dissociative steroid that preserves anti-inflammatory efficacy and decreases steroid-associated safety concerns. Ongoing extension studies offer the potential to bridge exploratory efficacy biomarkers to clinical outcomes.
    MeSH term(s) Administration, Oral ; Anti-Inflammatory Agents/blood ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Biomarkers/blood ; Blood Glucose/analysis ; Child ; Child, Preschool ; Humans ; Hydrocortisone/blood ; Insulin/blood ; Male ; Muscular Dystrophy, Duchenne/drug therapy ; Muscular Dystrophy, Duchenne/metabolism ; Pregnadienediols/blood ; Pregnadienediols/pharmacology ; Pregnadienediols/therapeutic use
    Chemical Substances Anti-Inflammatory Agents ; Biomarkers ; Blood Glucose ; Insulin ; Pregnadienediols ; VBP15 compound ; Hydrocortisone (WI4X0X7BPJ)
    Language English
    Publishing date 2018-09-13
    Publishing country Netherlands
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1003347-6
    ISSN 1096-1186 ; 0031-6989 ; 1043-6618
    ISSN (online) 1096-1186
    ISSN 0031-6989 ; 1043-6618
    DOI 10.1016/j.phrs.2018.09.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top